Akero soars as drug shows it reverses scarring in liver disease patients

By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse scarring of the organ without worsening the condition in a keenly awaited mid-stage trial. The experimental drug efruxifermin is being studied in patients with severe scarring due to a type of fatty liver disease known